[go: up one dir, main page]

MX2016006299A - Procesos para la preparación de compuestos de pirimidinilciclopentano. - Google Patents

Procesos para la preparación de compuestos de pirimidinilciclopentano.

Info

Publication number
MX2016006299A
MX2016006299A MX2016006299A MX2016006299A MX2016006299A MX 2016006299 A MX2016006299 A MX 2016006299A MX 2016006299 A MX2016006299 A MX 2016006299A MX 2016006299 A MX2016006299 A MX 2016006299A MX 2016006299 A MX2016006299 A MX 2016006299A
Authority
MX
Mexico
Prior art keywords
preparation
flexible substrate
wearable
useful
compound
Prior art date
Application number
MX2016006299A
Other languages
English (en)
Other versions
MX367620B (es
Inventor
Michelangelo Scalone
Hans Iding
Francis Gosselin
Reents Reinhard
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016006299A publication Critical patent/MX2016006299A/es
Publication of MX367620B publication Critical patent/MX367620B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/02Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from isocyanates with formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165Heterorings having nitrogen atoms as the only ring heteroatoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se relaciona con un proceso para la preparación de un compuesto de fórmula (I), donde R1 es como se define en la presente, que es útil como intermediario en la preparación de los compuestos farmacéuticos activos.
MX2016006299A 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano. MX367620B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13193030 2013-11-15
PCT/US2014/065567 WO2015073739A1 (en) 2013-11-15 2014-11-13 Processes for the preparation of pyrimidinylcyclopentane compounds

Publications (2)

Publication Number Publication Date
MX2016006299A true MX2016006299A (es) 2017-02-22
MX367620B MX367620B (es) 2019-08-28

Family

ID=49582648

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016006299A MX367620B (es) 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano.
MX2020009462A MX385726B (es) 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano.
MX2019006959A MX374852B (es) 2013-11-15 2014-11-13 Procesos para la preparacion de compuestos de pirimidinilciclopentano

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020009462A MX385726B (es) 2013-11-15 2014-11-13 Procesos para la preparación de compuestos de pirimidinilciclopentano.
MX2019006959A MX374852B (es) 2013-11-15 2014-11-13 Procesos para la preparacion de compuestos de pirimidinilciclopentano

Country Status (21)

Country Link
US (3) US9862689B2 (es)
EP (3) EP3656764B1 (es)
JP (4) JP6374503B2 (es)
KR (2) KR102698200B1 (es)
CN (3) CN105899492B (es)
AR (1) AR098427A1 (es)
AU (5) AU2014348570B2 (es)
CA (2) CA3207199A1 (es)
ES (2) ES2765511T3 (es)
HR (2) HRP20192340T1 (es)
HU (1) HUE063095T2 (es)
IL (3) IL245636B (es)
MX (3) MX367620B (es)
MY (2) MY174153A (es)
NZ (1) NZ720805A (es)
PL (2) PL3656764T3 (es)
RU (1) RU2702355C1 (es)
SG (1) SG10201901578UA (es)
SI (1) SI3068770T1 (es)
WO (1) WO2015073739A1 (es)
ZA (2) ZA201603434B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105899492B (zh) * 2013-11-15 2021-08-24 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
CA3190507A1 (en) 2014-09-26 2016-03-31 F. Hoffmann-La Roche Ag Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
CN116172869A (zh) 2016-08-10 2023-05-30 豪夫迈·罗氏有限公司 包含Akt蛋白激酶抑制剂的药物组合物
GB201802383D0 (en) * 2018-02-14 2018-03-28 Givaudan Sa Process

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6545165B1 (en) 2000-02-04 2003-04-08 Roche Colorado Corporation Synthesis of 3,6-dialkyl-5,6-dihydro-4-hydroxy-pyran-2-one
CN101180282B (zh) * 2005-05-24 2011-09-21 霍夫曼-拉罗奇有限公司 (s)-4-氟甲基-二氢-呋喃-2-酮的制备
CN101198594A (zh) * 2005-06-22 2008-06-11 尼科梅德有限责任公司 用于制备生产三环苯并咪唑类的中间体的方法
UA95641C2 (xx) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
KR20150041164A (ko) * 2006-07-06 2015-04-15 어레이 바이오파마 인크. Akt 단백질 키나제 억제제로서의 시클로펜타〔d〕피리미딘
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP2010536385A (ja) 2007-08-24 2010-12-02 コデクシス, インコーポレイテッド (r)−3−ヒドロキシチオランの立体選択的生成のための改善されたケトレダクターゼポリペプチド
US8853216B2 (en) 2008-01-09 2014-10-07 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor
AU2009204025B2 (en) 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
EP2329013B1 (en) 2008-08-27 2015-10-28 Codexis, Inc. Ketoreductase polypeptides for the production of a 3-aryl-3-hydroxypropanamine from a 3-aryl-3-ketopropanamine
US8273554B2 (en) 2008-08-29 2012-09-25 Codexis, Inc. Ketoreductase polypeptides for the stereoselective production of (4S)-3-[(5S)-5-(4-fluorophenyl)-5-hydroxypentanoyl]-4-phenyl-1,3-oxazolidin-2-one
US20110054174A1 (en) * 2009-08-28 2011-03-03 Stephan Bachmann Process for the preparation of a glucokinase activator compound
JP2013528787A (ja) 2010-04-16 2013-07-11 ジェネンテック, インコーポレイテッド Pi3k/aktキナーゼ経路インヒビターの効果の予測バイオマーカーとしてのfox03a
EP2694072B2 (en) 2011-04-01 2024-08-07 Genentech, Inc. Combination of akt inhibitor compound and abiraterone for use in therapeutic treatments
SG11201407591PA (en) * 2012-05-17 2015-01-29 Genentech Inc Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
LT2858989T (lt) * 2012-05-17 2020-08-10 Genentech, Inc. Akt inhibuojančio pirimidinil-ciklopentano junginio amorfinė forma, jo kompozicijos ir būdai
PL2861582T3 (pl) * 2012-05-17 2016-11-30 Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidynowych
PL2861583T3 (pl) 2012-05-17 2016-12-30 Sposób wytwarzania hydroksylowanych związków cyklopentylopirymidyny
ES2668477T3 (es) 2012-05-17 2018-05-18 Genentech, Inc. Proceso de preparación de compuestos de aminoácidos
CN105899492B (zh) 2013-11-15 2021-08-24 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
CA3190507A1 (en) 2014-09-26 2016-03-31 F. Hoffmann-La Roche Ag Processes for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds

Also Published As

Publication number Publication date
US20200062717A1 (en) 2020-02-27
EP3068770A4 (en) 2017-04-19
AU2014348570B2 (en) 2019-02-28
SI3068770T1 (sl) 2020-02-28
EP3656764C0 (en) 2023-07-05
HUE063095T2 (hu) 2023-12-28
JP2019218384A (ja) 2019-12-26
JP2021100953A (ja) 2021-07-08
ZA202002611B (en) 2023-10-25
EP4282973A2 (en) 2023-11-29
NZ720805A (en) 2022-01-28
PL3656764T3 (pl) 2024-01-22
IL271331B (en) 2021-03-25
MX2020009462A (es) 2021-08-31
EP3656764B1 (en) 2023-07-05
CN105899492A (zh) 2016-08-24
CN105899492B (zh) 2021-08-24
MY174153A (en) 2020-03-11
CA2930870C (en) 2023-09-19
JP7377828B2 (ja) 2023-11-10
AU2014348570A1 (en) 2016-06-09
EP4282973A3 (en) 2024-03-27
ZA201603434B (en) 2020-08-26
ES2957314T3 (es) 2024-01-17
AU2019202461A1 (en) 2019-05-02
CA3207199A1 (en) 2015-05-21
KR102698200B1 (ko) 2024-08-26
JP6857219B2 (ja) 2021-04-14
KR20220139440A (ko) 2022-10-14
HK1223102A1 (zh) 2017-07-21
EP3656764A1 (en) 2020-05-27
HRP20231100T1 (hr) 2023-12-22
IL245636A0 (en) 2016-06-30
AU2024205845A1 (en) 2024-09-05
BR112016011048A2 (pt) 2017-08-08
MX385726B (es) 2025-03-18
CN112898210B (zh) 2025-02-21
JP2018052966A (ja) 2018-04-05
CN112898210A (zh) 2021-06-04
KR102493603B1 (ko) 2023-01-31
IL245636B (en) 2019-12-31
CN110590606B (zh) 2023-02-17
IL281072A (en) 2021-04-29
MX374852B (es) 2025-03-06
RU2702355C1 (ru) 2019-10-08
SG10201901578UA (en) 2019-03-28
JP6374503B2 (ja) 2018-08-15
AU2021202196A1 (en) 2021-05-06
PL3068770T3 (pl) 2020-04-30
MY191759A (en) 2022-07-14
BR112016011048A8 (pt) 2020-04-22
ES2765511T3 (es) 2020-06-09
US20160297773A1 (en) 2016-10-13
WO2015073739A1 (en) 2015-05-21
JP6634428B2 (ja) 2020-01-22
JP2016539939A (ja) 2016-12-22
IL271331A (en) 2020-01-30
AU2022275477A1 (en) 2023-01-05
CA2930870A1 (en) 2015-05-21
HRP20192340T1 (hr) 2020-04-03
US10435378B2 (en) 2019-10-08
US20180086722A1 (en) 2018-03-29
US9862689B2 (en) 2018-01-09
MX367620B (es) 2019-08-28
RU2019130505A (ru) 2020-02-18
US10858324B2 (en) 2020-12-08
KR20160075816A (ko) 2016-06-29
CN110590606A (zh) 2019-12-20
AU2019202461B2 (en) 2021-01-14
MX2019006959A (es) 2019-08-01
IL281072B (en) 2022-05-01
EP3068770A1 (en) 2016-09-21
RU2016123365A (ru) 2017-12-18
AR098427A1 (es) 2016-05-26
EP3068770B1 (en) 2019-10-23

Similar Documents

Publication Publication Date Title
WO2014052506A3 (en) Facilitating affective feedback using wearable computing devices
WO2015108601A3 (en) Vibration energy compensation for a skin surface microphone ("ssm") in wearable communication devices
PH12015501082A1 (en) Pyridine -2-amides useful as cb2 agonists
SMT201700235T1 (it) Schema universale adattativo ed estensibile per dispositivi internet delle cose (iot) eterogenei
MX2021007988A (es) Sistema, metodo y aparato para el cuidado electronico de pacientes.
IN2014DN08965A (es)
MX2016006299A (es) Procesos para la preparación de compuestos de pirimidinilciclopentano.
PH12014501597A1 (en) Hand-held device for electrically assisted dermal treatment
TWD161468S (zh) 行動電話
TWD161469S (zh) 行動電話
TWD157803S (zh) 電子裝置之連接器
NZ715920A (en) Pesticidal compositions and processes related thereto
EA201590065A1 (ru) Аналоги глюкагона, проявляющие активность на рецепторе gip
WO2014195482A3 (en) Organic electronic device
TWD166670S (zh) 電纜連接器之引線框組件
EP4202959A3 (en) Overvoltage protection devices including wafer of varistor material
MX2015010152A (es) Dispositivos implantables, miniaturizados de sensor electroquimico.
MY157390A (en) Switching circuit and semiconductor module
EP2634809A3 (en) Field effect transistor
BR112014029731A2 (pt) vidro com um elemento de conexão elétrica
WO2014074953A3 (en) Multimodal physiological sensing for wearable devices or mobile devices
DE102018214362B8 (de) Direkt am gerät zu montierender abschirmverbinder
BR112013002212A2 (pt) carboxamidas aza-heterocíclicas de aminas cíclicas
WO2012114306A3 (en) Feedthrough having a non-linear conductor
PL2876138T3 (pl) Materiał silikonowy do ochrony urządzeń elektronicznych, wykorzystujący go moduł obwodu i metoda wytwarzania modułu obwodu

Legal Events

Date Code Title Description
FG Grant or registration